<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Neuropsychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Neuropsychopharmacol</journal-id><journal-id journal-id-type="publisher-id">ijnp</journal-id><journal-title-group><journal-title>International Journal of Neuropsychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">1461-1457</issn><issn pub-type="epub">1469-5111</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5616354</article-id><article-id pub-id-type="doi">10.1093/ijnp/pyw041.419</article-id><article-id pub-id-type="publisher-id">pyw041.419</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Monday Abstracts</subject></subj-group></subj-group></article-categories><title-group><article-title>PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Savitz</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gopal</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhuo</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nuamah</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hough</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mathews</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Janssen Research &#x00026; Development, New Jersey, USA</aff><aff id="aff2">
<label>2</label>Janssen Research &#x00026; Development, Beijing, China</aff><pub-date pub-type="collection"><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub" iso-8601-date="2016-05-27"><day>27</day><month>5</month><year>2016</year></pub-date><volume>19</volume><issue>Suppl 1</issue><fpage seq="b">52</fpage><lpage>52</lpage><permissions><copyright-statement>&#x000a9; The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</copyright-statement><copyright-year>2016</copyright-year></permissions><self-uri xlink:href="pyw041.419.pdf"/><counts><page-count count="1"/></counts></article-meta></front><body><p>
<bold>Abstract</bold>
</p><p>
<bold>Background:</bold> The current study was designed to demonstrate noninferiority of paliperidone palmitate 3-monthly formulation (PP3M) to PP 1-monthly formulation (PP1M) in Asian patients (China, Japan, Korea and Taiwan) with schizophrenia.</p><p>
<bold>Methods:</bold> Eligible patients (18&#x02013;70 years) entered 17-week, flexible-dose, open-label (OL) phase to receive PP1M. Stabilized patients were randomized (1:1) to receive fixed doses of PP1M or PP3M (175, 263, 350, or 525&#x02009;mg eq.) in a 48-week, double-blind (DB) phase.</p><p>
<bold>Results:</bold> Total 510 Asian patients were enrolled and dosed in OL phase (total population: n=1429; China: n=296, Japan: n=175, Korea: n=19, Taiwan: n=20); 344 Asian patients were randomized in DB phase (total population: PP3M=504; PP1M=512; China: PP3M=104; PP1M=106; Japan: PP3M=52; PP1M=56; Korea: PP3M=7; PP1M=5; Taiwan: PP3M=7; PP1M=7). The Kaplan-Meier estimate of the difference (95% CI) between the treatment groups (PP3M-PP1M) in percentages of patients who remained relapse free (primary efficacy endpoint) was similar in the larger 2 subgroups (China: 1.1% [-6.1%; 8.3%]; Japan: 5.1% [-12.0%; 22.2%]) and the total population (1.2% [-2.7%; 5.1%]); the lower bounds of the 95% CI for all subgroups were larger than the pre-specified non-inferiority margin of -15%. Incidences of treatment-emergent adverse events (TEAEs) during the OL phase (China: 198/296 [66.9%]; Japan: 132/175 [75.4%]) as well as DB phase (China: 149/210 [71.0%]; Japan: 99/108 [91.7%]) were higher in the larger 2 subgroups versus the total population (OL total population: 846/1429 [59.2%]; DB total population 682/1016 [67.1%]). Increased weight was the most frequent (&#x02265;20%) TEAE during the DB phase (PP3M vs. PP1M, China: 36.5% vs. 34.9%; Japan: 25.0% vs. 19.6%).</p><p>
<bold>Conclusions:</bold> PP3M was non-inferior to PP1M and was similarly tolerable in both total population, and Asian patients with schizophrenia.</p></body></article>